|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
mood stabilizer
|
|
gptkbp:activeIngredient
|
gptkb:valproic_acid
|
|
gptkbp:ATCCode
|
N03AG01
|
|
gptkbp:brand
|
gptkb:Depakene
gptkb:Depakote
gptkb:Epilim
|
|
gptkbp:CASNumber
|
1069-66-5
|
|
gptkbp:chemicalFormula
|
C8H15NaO2
|
|
gptkbp:contraindication
|
gptkb:liver_disease
pregnancy
|
|
gptkbp:discoveredBy
|
gptkb:Pierre_Eymard
|
|
gptkbp:discoveredIn
|
1962
|
|
gptkbp:drugInteraction
|
gptkb:rifampicin
gptkb:phenytoin
gptkb:warfarin
gptkb:aspirin
gptkb:carbamazepine
gptkb:erythromycin
gptkb:lamotrigine
cimetidine
phenobarbital
felbamate
|
|
gptkbp:eliminationHalfLife
|
9-16 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sodium valproate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks voltage-gated sodium channels
increases GABA levels
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:riskOfBirthDefects
|
high
|
|
gptkbp:riskOfHepatotoxicity
|
yes
|
|
gptkbp:riskOfHyperammonemia
|
yes
|
|
gptkbp:riskOfPancreatitis
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
tremor
hair loss
pancreatitis
weight gain
drowsiness
liver toxicity
teratogenicity
|
|
gptkbp:usedFor
|
bipolar disorder
epilepsy
migraine prophylaxis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Epilim
|
|
gptkbp:bfsLayer
|
7
|